Cargando…

Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports

INTRODUCTION: Thromboembolic events with the use of immune checkpoint inhibitors (ICIs) in patients with cancer have been reported in few studies. However, the detailed profile of these cases remains mostly uncertain. METHOD: A descriptive analysis of Thromboembolic events associated with ICIs retri...

Descripción completa

Detalles Bibliográficos
Autores principales: Alghamdi, Eman A., Aljohani, Hadir, Alghamdi, Waad, Alharbi, Fawaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508630/
https://www.ncbi.nlm.nih.gov/pubmed/36164566
http://dx.doi.org/10.1016/j.jsps.2022.06.010
_version_ 1784797058203385856
author Alghamdi, Eman A.
Aljohani, Hadir
Alghamdi, Waad
Alharbi, Fawaz
author_facet Alghamdi, Eman A.
Aljohani, Hadir
Alghamdi, Waad
Alharbi, Fawaz
author_sort Alghamdi, Eman A.
collection PubMed
description INTRODUCTION: Thromboembolic events with the use of immune checkpoint inhibitors (ICIs) in patients with cancer have been reported in few studies. However, the detailed profile of these cases remains mostly uncertain. METHOD: A descriptive analysis of Thromboembolic events associated with ICIs retrieved from the VigiBase, between 1967 to November 2020. We extracted the data using the terms of ‘pulmonary embolism’ OR ‘deep vein thrombosis’ OR ‘acute coronary syndrome’ OR ‘myocardial infarction’ OR ‘ischemic stroke’ (preferred term (PT) (MedDRA). RESULTS: We included 161 cases from 26 countries in our descriptive analysis. Patients’ ages were reported in 141 (87.6%) cases, with a median of 68 years (interquartile range 61–74), and 63.4% of the patients were male. Indications for ICIs were reported in 151 (93.8%) cases, as follows: lung cancer (n = 85, 52.8%), renal cell carcinoma (n = 24, 14.9%), melanoma (n = 20, 12.4%), urethral carcinoma (n = 12, 7.45%), breast cancer (n = 4, 2.48%), adenocarcinoma of the gastroesophageal junction (n = 3, 1.9%), gastric cancer (n = 2, 1.24%), and skin cancer (n = 1, 0.62%). Nivolumab was reported as a suspected drug in 76 cases (47%), pembrolizumab in 46 cases (28.5%), atezolizumab in 21 cases (13%), durvalumab in 14 cases (8.6%), and avelumab in four cases (2.4%). The time to onset of thromboembolic events was reported in 127 (78.8%) cases. Most of these patients (n = 109, 85.8%) reported thromboembolic events within the first six months. The causality assessment of included cases showed that 50.3% of reported thromboembolic events were possibly related to the suspected reported medication, 13.7% were probably related, 13% were unlikely to be related, and 23% were not assessable due to insufficient information. CONCLUSION: This study demonstrates a possible association between the use of ICIs and thromboembolic events. Further epidemiological studies are needed to assess this association and to elucidate the underlying mechanism.
format Online
Article
Text
id pubmed-9508630
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95086302022-09-25 Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports Alghamdi, Eman A. Aljohani, Hadir Alghamdi, Waad Alharbi, Fawaz Saudi Pharm J Original Article INTRODUCTION: Thromboembolic events with the use of immune checkpoint inhibitors (ICIs) in patients with cancer have been reported in few studies. However, the detailed profile of these cases remains mostly uncertain. METHOD: A descriptive analysis of Thromboembolic events associated with ICIs retrieved from the VigiBase, between 1967 to November 2020. We extracted the data using the terms of ‘pulmonary embolism’ OR ‘deep vein thrombosis’ OR ‘acute coronary syndrome’ OR ‘myocardial infarction’ OR ‘ischemic stroke’ (preferred term (PT) (MedDRA). RESULTS: We included 161 cases from 26 countries in our descriptive analysis. Patients’ ages were reported in 141 (87.6%) cases, with a median of 68 years (interquartile range 61–74), and 63.4% of the patients were male. Indications for ICIs were reported in 151 (93.8%) cases, as follows: lung cancer (n = 85, 52.8%), renal cell carcinoma (n = 24, 14.9%), melanoma (n = 20, 12.4%), urethral carcinoma (n = 12, 7.45%), breast cancer (n = 4, 2.48%), adenocarcinoma of the gastroesophageal junction (n = 3, 1.9%), gastric cancer (n = 2, 1.24%), and skin cancer (n = 1, 0.62%). Nivolumab was reported as a suspected drug in 76 cases (47%), pembrolizumab in 46 cases (28.5%), atezolizumab in 21 cases (13%), durvalumab in 14 cases (8.6%), and avelumab in four cases (2.4%). The time to onset of thromboembolic events was reported in 127 (78.8%) cases. Most of these patients (n = 109, 85.8%) reported thromboembolic events within the first six months. The causality assessment of included cases showed that 50.3% of reported thromboembolic events were possibly related to the suspected reported medication, 13.7% were probably related, 13% were unlikely to be related, and 23% were not assessable due to insufficient information. CONCLUSION: This study demonstrates a possible association between the use of ICIs and thromboembolic events. Further epidemiological studies are needed to assess this association and to elucidate the underlying mechanism. Elsevier 2022-08 2022-06-21 /pmc/articles/PMC9508630/ /pubmed/36164566 http://dx.doi.org/10.1016/j.jsps.2022.06.010 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Alghamdi, Eman A.
Aljohani, Hadir
Alghamdi, Waad
Alharbi, Fawaz
Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
title Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
title_full Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
title_fullStr Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
title_full_unstemmed Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
title_short Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
title_sort immune checkpoint inhibitors and potential risk of thromboembolic events: analysis of the who global database of individual case safety reports
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508630/
https://www.ncbi.nlm.nih.gov/pubmed/36164566
http://dx.doi.org/10.1016/j.jsps.2022.06.010
work_keys_str_mv AT alghamdiemana immunecheckpointinhibitorsandpotentialriskofthromboemboliceventsanalysisofthewhoglobaldatabaseofindividualcasesafetyreports
AT aljohanihadir immunecheckpointinhibitorsandpotentialriskofthromboemboliceventsanalysisofthewhoglobaldatabaseofindividualcasesafetyreports
AT alghamdiwaad immunecheckpointinhibitorsandpotentialriskofthromboemboliceventsanalysisofthewhoglobaldatabaseofindividualcasesafetyreports
AT alharbifawaz immunecheckpointinhibitorsandpotentialriskofthromboemboliceventsanalysisofthewhoglobaldatabaseofindividualcasesafetyreports